Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1987 Aug;147(2):181–186.

New Approaches to Treating Systemic Lupus Erythematosus

PMCID: PMC1025772  PMID: 3310402

Abstract

These discussions are selected from the weekly staff conferences in the Department of Medicine, University of California, San Francisco. Taken from transcriptions, they are prepared by Drs Homer A. Boushey, Associate Professor of Medicine, and David G. Warnock, Associate Professor of Medicine, under the direction of Dr Lloyd H. Smith, Jr, Professor of Medicine and Associate Dean in the School of Medicine. Requests for reprints should be sent to the Department of Medicine, University of California, San Francisco, School of Medicine, San Francisco, CA 94143.

Full text

PDF
181

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adelman N. E., Watling D. L., McDevitt H. O. Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies. J Exp Med. 1983 Oct 1;158(4):1350–1355. doi: 10.1084/jem.158.4.1350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arnett F. C., Reveille J. D., Wilson R. W., Provost T. T., Bias W. B. Systemic lupus erythematosus: current state of the genetic hypothesis. Semin Arthritis Rheum. 1984 Aug;14(1):24–35. doi: 10.1016/0049-0172(84)90006-4. [DOI] [PubMed] [Google Scholar]
  3. Austin H. A., 3rd, Klippel J. H., Balow J. E., le Riche N. G., Steinberg A. D., Plotz P. H., Decker J. L. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986 Mar 6;314(10):614–619. doi: 10.1056/NEJM198603063141004. [DOI] [PubMed] [Google Scholar]
  4. Austin H. A., 3rd, Muenz L. R., Joyce K. M., Antonovych T. A., Kullick M. E., Klippel J. H., Decker J. L., Balow J. E. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med. 1983 Sep;75(3):382–391. doi: 10.1016/0002-9343(83)90338-8. [DOI] [PubMed] [Google Scholar]
  5. Ballou S. P., Khan M. A., Kushner I. Intravenous pulse methylprednisolone followed by alternate day corticosteroid therapy in lupus erythematosus: a prospective evaluation. J Rheumatol. 1985 Oct;12(5):944–948. [PubMed] [Google Scholar]
  6. Balow J. E., Austin H. A., 3rd, Muenz L. R., Joyce K. M., Antonovych T. T., Klippel J. H., Steinberg A. D., Plotz P. H., Decker J. L. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med. 1984 Aug 23;311(8):491–495. doi: 10.1056/NEJM198408233110802. [DOI] [PubMed] [Google Scholar]
  7. Balow J. E., Austin H. A., 3rd, Tsokos G. C., Antonovych T. T., Steinberg A. D., Klippel J. H. NIH conference. Lupus nephritis. Ann Intern Med. 1987 Jan;106(1):79–94. doi: 10.7326/0003-4819-106-1-79. [DOI] [PubMed] [Google Scholar]
  8. Bell P. R., Briggs J. D., Calman K. C., Paton A. M., Wood R. F., Macpherson S. G., Kyle K. Reversal of acute clinical and experimental organ rejection using large doses of intravenous prednisolone. Lancet. 1971 May 1;1(7705):876–880. doi: 10.1016/s0140-6736(71)92441-x. [DOI] [PubMed] [Google Scholar]
  9. Ben-Chetrit E., Gross D. J., Braverman A., Weshler Z., Fuks Z., Slavin S., Eliakim M. Total lymphoid irradiation in refractory systemic lupus erythematosus. Ann Intern Med. 1986 Jul;105(1):58–60. doi: 10.7326/0003-4819-105-1-58. [DOI] [PubMed] [Google Scholar]
  10. Feinglass E. J., Arnett F. C., Dorsch C. A., Zizic T. M., Stevens M. B. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore) 1976 Jul;55(4):323–339. doi: 10.1097/00005792-197607000-00004. [DOI] [PubMed] [Google Scholar]
  11. Felson D. T., Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med. 1984 Dec 13;311(24):1528–1533. doi: 10.1056/NEJM198412133112402. [DOI] [PubMed] [Google Scholar]
  12. Fries J. F., Porta J., Liang M. H. Marginal benefit of renal biopsy in systemic lupus erythematosus. Arch Intern Med. 1978 Sep;138(9):1386–1389. [PubMed] [Google Scholar]
  13. Fuks Z., Strober S., Bobrove A. M., Sasazuki T., McMichael A., Kaplan H. S. Long term effects of radiation of T and B lymphocytes in peripheral blood of patients with Hodgkin's disease. J Clin Invest. 1976 Oct;58(4):803–814. doi: 10.1172/JCI108532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hahn B. H., Ebling F. M. Idiotype restriction in murine lupus; high frequency of three public idiotypes on serum IgG in nephritic NZB/NZW F1 mice. J Immunol. 1987 Apr 1;138(7):2110–2118. [PubMed] [Google Scholar]
  15. Hahn B. H., Ebling F. M. Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA. J Immunol. 1984 Jan;132(1):187–190. [PubMed] [Google Scholar]
  16. Hoch S., Schur P. H. Methylprednisolone pulse therapy for lupus nephritis: a followup study. Clin Exp Rheumatol. 1984 Oct-Dec;2(4):313–320. [PubMed] [Google Scholar]
  17. Huestis D. W. Mortality in therapeutic haemapheresis. Lancet. 1983 May 7;1(8332):1043–1043. doi: 10.1016/s0140-6736(83)92664-8. [DOI] [PubMed] [Google Scholar]
  18. Isenberg D. A., Collins C. Detection of cross-reactive anti-DNA antibody idiotypes on renal tissue-bound immunoglobulins from lupus patients. J Clin Invest. 1985 Jul;76(1):287–294. doi: 10.1172/JCI111959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. JESSAR R. A., LAMONT-HAVERS R. W., RAGAN C. Natural history of lupus erythematosus disseminatus. Ann Intern Med. 1953 Apr;38(4):717–731. doi: 10.7326/0003-4819-38-4-717. [DOI] [PubMed] [Google Scholar]
  20. Jarrett M. P., Sablay L. B., Walter L., Barland P., Grayzel A. I. The effect of continuous normalization of serum hemolytic complement on the course of lupus nephritis: a five year prospective study. Am J Med. 1981 May;70(5):1067–1072. doi: 10.1016/0002-9343(81)90870-6. [DOI] [PubMed] [Google Scholar]
  21. Jones J. V., Cumming R. H., Bacon P. A., Evers J., Fraser I. D., Bothamley J., Tribe C. R., Davis P., Hughes G. R. Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus. Q J Med. 1979 Oct;48(192):555–576. [PubMed] [Google Scholar]
  22. Jones J. V., Robinson M. F., Parciany R. K., Layfer L. F., McLeod B. Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA. Arthritis Rheum. 1981 Sep;24(9):1113–1120. doi: 10.1002/art.1780240901. [DOI] [PubMed] [Google Scholar]
  23. Kimberly R. P., Lockshin M. D., Sherman R. L., McDougal J. S., Inman R. D., Christian C. L. High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. Am J Med. 1981 Apr;70(4):817–824. doi: 10.1016/0002-9343(81)90538-6. [DOI] [PubMed] [Google Scholar]
  24. Kotzin B. L., Strober S. Reversal of nzb/nzw disease with total lymphoid irradiation. J Exp Med. 1979 Aug 1;150(2):371–378. doi: 10.1084/jem.150.2.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kremer J. M., Jubiz W., Michalek A., Rynes R. I., Bartholomew L. E., Bigaouette J., Timchalk M., Beeler D., Lininger L. Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study. Ann Intern Med. 1987 Apr;106(4):497–503. doi: 10.7326/0003-4819-106-4-497. [DOI] [PubMed] [Google Scholar]
  26. Lee T. H., Hoover R. L., Williams J. D., Sperling R. I., Ravalese J., 3rd, Spur B. W., Robinson D. R., Corey E. J., Lewis R. A., Austen K. F. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med. 1985 May 9;312(19):1217–1224. doi: 10.1056/NEJM198505093121903. [DOI] [PubMed] [Google Scholar]
  27. Leonhardt T. Long-term prognosis of systemic lupus erythematosus. Acta Med Scand Suppl. 1966;445:440–443. doi: 10.1111/j.0954-6820.1966.tb02397.x. [DOI] [PubMed] [Google Scholar]
  28. Liebling M. R., McLaughlin K., Boonsue S., Kasdin J., Barnett E. V. Monthly pulses of methylprednisolone in SLE nephritis. J Rheumatol. 1982 Jul-Aug;9(4):543–548. [PubMed] [Google Scholar]
  29. Magil A. B., Ballon H. S., Chan V., Lirenman D. S., Rae A., Sutton R. A. Diffuse proliferative lupus glomerulonephritis. Determination of prognostic significance of clinical, laboratory and pathologic factors. Medicine (Baltimore) 1984 Jul;63(4):210–220. [PubMed] [Google Scholar]
  30. Oredugba O., Mazumdar D. C., Meyer J. S., Lubowitz H. Pulse methylprednisolone therapy in idiopathic, rapidly progressive glomerulonephritis. Ann Intern Med. 1980 Apr;92(4):504–506. doi: 10.7326/0003-4819-92-4-504. [DOI] [PubMed] [Google Scholar]
  31. Ponticelli C., Zucchelli P., Banfi G., Cagnoli L., Scalia P., Pasquali S., Imbasciati E. Treatment of diffuse proliferative lupus nephritis by intravenous high-dose methylprednisolone. Q J Med. 1982;51(201):16–24. [PubMed] [Google Scholar]
  32. Prickett J. D., Robinson D. R., Steinberg A. D. Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB x NZW F1 mice. J Clin Invest. 1981 Aug;68(2):556–559. doi: 10.1172/JCI110288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Prickett J. D., Trentham D. E., Robinson D. R. Dietary fish oil augments the induction of arthritis in rats immunized with type II collagen. J Immunol. 1984 Feb;132(2):725–729. [PubMed] [Google Scholar]
  34. Reinertsen J. L., Klippel J. H., Johnson A. H., Steinberg A. D., Decker J. L., Mann D. L. B-lymphocyte alloantigens associated with systemic lupus erythematosus. N Engl J Med. 1978 Sep 7;299(10):515–518. doi: 10.1056/NEJM197809072991004. [DOI] [PubMed] [Google Scholar]
  35. Shumak K. H., Rock G. A. Therapeutic plasma exchange. N Engl J Med. 1984 Mar 22;310(12):762–771. doi: 10.1056/NEJM198403223101206. [DOI] [PubMed] [Google Scholar]
  36. Strober S., Field E., Hoppe R. T., Kotzin B. L., Shemesh O., Engleman E., Ross J. C., Myers B. D. Treatment of intractable lupus nephritis with total lymphoid irradiation. Ann Intern Med. 1985 Apr;102(4):450–458. doi: 10.7326/0003-4819-102-4-450. [DOI] [PubMed] [Google Scholar]
  37. The treatment of the nephritis of lupus erythematosus. West J Med. 1977 Jun;126(6):479–484. [PMC free article] [PubMed] [Google Scholar]
  38. Tsokos G. C., Balow J. E. Immunosuppressive agents and plasmapheresis in immunological disorders. J Immunopharmacol. 1985;7(1):1–15. doi: 10.3109/08923978509026465. [DOI] [PubMed] [Google Scholar]
  39. Urman J. D., Rothfield N. F. Corticosteroid treatment in systemic lupus erythematosus. Survival studies. JAMA. 1977 Nov 21;238(21):2272–2276. [PubMed] [Google Scholar]
  40. Valentijn R. M., van Overhagen H., Hazevoet H. M., Hermans J., Cats A., Daha M. R., van ES L. A. The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 1985 Aug;28(8):904–913. doi: 10.1002/art.1780280810. [DOI] [PubMed] [Google Scholar]
  41. Wallace D. J., Goldfinger D., Bluestone R., Klinenberg J. R. Plasmapheresis in lupus nephritis with nephrotic syndrome: a long-term followup. J Clin Apher. 1982;1(1):42–45. doi: 10.1002/jca.2920010109. [DOI] [PubMed] [Google Scholar]
  42. Wei N., Klippel J. H., Huston D. P., Hall R. P., Lawley T. J., Balow J. E., Steinberg A. D., Decker J. L. Randomised trial of plasma exchange in mild systemic lupus erythematosus. Lancet. 1983 Jan 1;1(8314-5):17–22. doi: 10.1016/s0140-6736(83)91561-1. [DOI] [PubMed] [Google Scholar]
  43. Whiting-O'Keefe Q., Henke J. E., Shearn M. A., Hopper J., Jr, Biava C. G., Epstein W. V. The information content from renal biopsy in systemic lupus erythematosus. Ann Intern Med. 1982 Jun;96(6 Pt 1):718–723. doi: 10.7326/0003-4819-96-6-718. [DOI] [PubMed] [Google Scholar]
  44. Whiting-O'Keefe Q., Riccardi P. J., Henke J. E., Shearn M. A., Hopper J., Jr, Epstein W. V. Recognition of information in renal biopsies of patients with lupus nephritis. Ann Intern Med. 1982 Jun;96(6 Pt 1):723–727. doi: 10.7326/0003-4819-96-6-723. [DOI] [PubMed] [Google Scholar]
  45. Wofsy D., Seaman W. E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985 Feb 1;161(2):378–391. doi: 10.1084/jem.161.2.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Wofsy D. Strategies for treating autoimmune disease with monoclonal antibodies. West J Med. 1985 Dec;143(6):804–809. [PMC free article] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES